Single chain variable fragment antibodies against shiga toxins isolated from a human antibody phage display library

Vaccine

Volumn 29, Issue 33, 2011, Pages 5340-5346

  Neri, Paola ^a   Shigemori, Naoko ^a   Hamada Tsutsumi, Susumu ^b   Tsukamoto, Kentaro ^a   Arimitsu, Hideyuki ^a   Shimizu, Toshiyasu ^a   Akahori, Yasushi ^b   Kurosawa, Yoshikazu ^b   Tsuji, Takao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Neutralization; Phage display; Shiga toxin; Single chain variable fragment antibody

Indexed keywords

ANTIBODY B22; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; SHIGA TOXIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2;

ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL;

ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; HUMANS; PEPTIDE LIBRARY; PROTEIN BINDING; SHIGA TOXINS; SINGLE-CHAIN ANTIBODIES;

EID: 79960380767     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.093     Document Type: Article

References (28)

1. Paton J.C., Paton A.W. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 1998, 11:450-479.
2. Karmali M.A., Petric M., Lim C., Fleming P.C., Arbus G.S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985, 151:775-782.
3. Hurley B.P., Jacewicz M., Thorpe C.M., Lincicome L.L., King A.J., Keusch G.T., et al. Shiga toxin 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect Immun 1999, 67:6670-6677.
4. Lindberg A.A., Brown J.E., Stromberg N., Westling-Ryd M., Schultz J.E., Karlsson K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem 1987, 262:1779-1785.
5. Scotland S.M., Smith H.R., Rowe B. Two distinct toxins active on Vero cells from Escherichia coli O157. Lancet 1985, 2:885-886.
6. Strockbine N.A., Marques L.R., Newland J.W., Smith H.W., Holmes R.K., O'Brien A.D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 1986, 53:135-140.
7. Jackson M.P., Neill R.J., O'Brien A.D., Holmes R.K., Newland J.W. Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett 1987, 44:109-114.
8. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara T., Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988, 171:45-50.
9. Wong C.S., Jelacic S., Habeeb R.L., Watkins S.L., Tarr P.I. The risk of the hemolytic-uremic syndrome after antibiotics treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000, 342:1930-1936.
10. Mulvey G.L., Marcato P., Kitov P.I., Sadowska J., Bundle D.R., Armstrong G.D. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 2003, 187:640-649.
11. Watanabe M., Matsuoka K., Kita E., Igai K., Higashi N., Miyagawa A., et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 2004, 189:360-368.
12. Nishikawa K., Matsuoka K., Watanabe M., Igai K., Hino K., Hatano K., et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 2005, 191:2097-2105.
13. Neri P., Nagano I.S., Yokoyama S., Dohi H., Kobayashi K., Miura T., et al. Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins. Microbiol Immunol 2007, 51:581-592.
14. Neri P., Tokoro S., Yokoyama S., Miura T., Murata T., Nishida Y., et al. Monovalent Gb3-/Gb2-derivatives conjugated with a phosphatidyl residue: a novel class of Shiga toxin-neutralizing agent. Biol Pharm Bull 2007, 30:1697-1701.
15. Mukherjee J., Chios K., Fishwild D., Hudson D., O'Donnell S., Rich S.M., et al. Production and characterization of protective human antibodies against Shiga Toxin 1. Infect Immun 2002, 70:5896-5899.
16. Dowling T.C., Chavaillaz P.A., Young D.G., Melton-Celsa A., O'Brien A.D., Thuning-Roberson C., et al. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 2005, 49:1808-1812.
17. Krautz-Peterson G., Chapman-Bonofiglio S., Boisvert K., Feng H., Herman I.M., Tzipori S., et al. Intracellular neutralization of Shiga toxin 2 by an A subunit-specific human monoclonal antibody. Infect Immun 2008, 6:1931-1939.
18. Smith M.J., Melton-Chelsa A.R., Sinclair J.F., Carvalho H.M., Robinson C.M., O'Brien A.D. Monoclonal antibody 11E10, which neutralizes Shiga Toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin. Infect Immun 2009, 77:2730-2740.
19. Arap M.A. Phage display technology-applications and innovations. Gen Mol Biol 2005, 28:1-9.
20. Hollinger P., Hudson P. Engineered antibody fragments and the rise of single domain. Nat Biotechnol 2005, 23:1126-1136.
21. Pansri P., Jaruseranee N., Rangnoi K., Kristensen P., Yamabhai M. A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol 2009, 9:6.
22. Morino K., Katsumi H., Akahori Y., Iba Y., Shinohara M., Ukai Y., et al. Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression. J Immunol Methods 2001, 257:175-184.
23. Shimizu T., Kawakami S., Sato T., Sasaki T., Higashide M., Hamabata T., et al. Serine 31 residue of B subunit of Shiga toxin 2 is essential for the secretion in Enterohemorrhagic Escherichia coli. Infect Immun 2007, 75:2189-2200.
24. Tsuji T., Shimizu T., Sasaki K., Shimizu Y., Tsukamoto K., Arimitsu H., et al. Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 2008, 26:469-476.
25. Fraser M.E., Fujinaga M., Cherney M.M., Melton-Celsa A.R., Twiddy E.M., O'Brien A.D., et al. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J Biol Chem 2004, 279:27511-27517.
26. Tsuji T., Shimizu T., Sasaki K., Tsukamoto K., Arimitsu H., Ochi S., et al. A nasal vaccine comprising B-subunit derivative of Shiga toxin 2 for cross-protection against Shiga toxin types 1 and 2. Vaccine 2008, 26:2092-2099.
27. Terskikh A.V., Le Doussal J.M., Cramieri R., Fisch I., Mach J.P., Kajava A.V. Peptabody: a new type of high avidity binding protein. Proc Natl Acad Sci USA 1997, 94:1663-1668.
28. Gherardi E., Milstein C. Original and artificial antibodies. Nature 1992, 357:201-202.